Who are BMS-650032 (Asunaprevir)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Viekira Pak ± ribavirin, Daclatasvir plus Asunaprevir, Elbasvir/Grazoprevir, Elbasvir / Grazoprevir Oral Tablet [Zepatier], ABT-450/ritonavir, Cross-Over Boceprevir Treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bms-650032-asunaprevir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

BMS-650032 (Asunaprevir) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BMS-650032 (Asunaprevir) (BMS-650032 (Asunaprevir)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HCV NS3 protease inhibitor. Area: Virology / Hepatology.

phase 3 HCV NS3 protease inhibitor HCV NS3/4A serine protease Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

BMS-650032 (Asunaprevir) (BMS-650032 (Asunaprevir)) — Bristol-Myers Squibb. Asunaprevir is a hepatitis C virus (HCV) NS3 protease inhibitor that blocks viral protein processing and replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BMS-650032 (Asunaprevir) TARGET	BMS-650032 (Asunaprevir)	Bristol-Myers Squibb	phase 3	HCV NS3 protease inhibitor	HCV NS3/4A serine protease
Viekira Pak ± ribavirin	Viekira Pak ± ribavirin	Massachusetts General Hospital	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein, HCV NS3/4A serine protease
Daclatasvir plus Asunaprevir	Daclatasvir plus Asunaprevir	Myeong Jun Song	marketed	Direct-acting antiviral combination (NS5A inhibitor + NS3/4A protease inhibitor)	HCV NS5A protein and HCV NS3/4A serine protease
Elbasvir/Grazoprevir	Elbasvir/Grazoprevir	University of Florence	marketed	Direct-acting antiviral (DAA) combination; NS5A inhibitor + NS3/4A protease inhibitor	HCV NS5A protein and HCV NS3/4A serine protease
Elbasvir / Grazoprevir Oral Tablet [Zepatier]	Elbasvir / Grazoprevir Oral Tablet [Zepatier]	University of Maryland, Baltimore	marketed	Direct-acting antiviral (DAA) combination	HCV NS5A protein and HCV NS3/4A serine protease
ABT-450/ritonavir	ABT-450/ritonavir	AbbVie (prior sponsor, Abbott)	phase 3	Hepatitis C virus NS3/4A protease inhibitor	HCV NS3/4A serine protease
Cross-Over Boceprevir Treatment	Cross-Over Boceprevir Treatment	Merck Sharp & Dohme LLC	phase 3	HCV NS3 protease inhibitor	HCV NS3/4A serine protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HCV NS3 protease inhibitor class)

Merck Sharp & Dohme LLC · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BMS-650032 (Asunaprevir) — Competitive Intelligence Brief. https://druglandscape.com/ci/bms-650032-asunaprevir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab